Clinical trial Recruiting at 1 site Observational Women only

Transabdominal vs. Transvaginal Ultrasound in high-risk pregnancies during early weeks

Official title: Transabdominal Ultrasound Versus Transvaginal Ultrasound at 9-14 Weeks in High-Risk Pregnancies: A Comparative Study

Run by Al-Azhar University · NCT07883850 · Data updated 2026-11-12

This study tests whether transabdominal ultrasound can visualize fetal structures as well as transvaginal ultrasound in high-risk singleton pregnancies between 9 and 13+6 weeks.

Quick facts

Study typeObservational
SexWomen only
Enrollment200 (estimated)
SponsorAl-Azhar University
Academic / other
Locations1 site (Asyut)
StatusRecruiting
StartedJuly 1, 2026
Main results expectedApril 30, 2027
Study endsMay 31, 2027
Registry record updatedOctober 21, 2026
Trial IDNCT07883850 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Pregnant women with a singleton viable pregnancy at 9+0 to 13+6 weeks who are at increased risk of fetal congenital anomalies and consent to both TAUS and TVUS.

Probably not a fit

Participants with no improvement in visualization using TAUS or who have conditions where TVUS remains superior may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study compares the visualization success of two ultrasound approaches within the same participants who have high-risk singleton pregnancies. Women between 9+0 and 13+6 weeks gestation will receive both transabdominal and transvaginal scans to assess predefined fetal and pregnancy-related structures. The primary goal is to determine which method more reliably visualizes key anatomy and detects major fetal abnormalities in early pregnancy. The study acknowledges factors like gestational age and maternal body habitus that can affect image quality, and will record visualization status for each structure. It is conducted at Al-Azhar University Hospital in Assiut, Egypt with participation limited to eligible women who consent to both imaging modalities.

Why it matters

Potential benefit: If TAUS proves comparably effective, many patients could avoid transvaginal scans while maintaining accurate early fetal assessment.

How similar studies have gone: Previous work in early ultrasound has shown method-dependent visualization differences, but direct within-subject comparison at these gestational windows is relatively novel in this setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnancy at increased risk of fetal congenital anomalies, based on the clinical assessment and predefined high-risk criteria of the study protocol..
* Acceptance of both transabdominal and transvaginal ultrasound examinations No minimum or maximum age restriction is specified in the current protocol..
* Gestational age between 9+0 and 13+6 weeks, confirmed by crown-rump length measurement at enrollment
* Pregnant women with a singleton viable intrauterine pregnancy..

Exclusion Criteria:

* Multiple pregnancy..
* Previously diagnosed fetal anomaly Refusal of transvaginal ultrasound examination.
* Non-viable pregnancy, including missed miscarriage or an embryonic pregnancy, at the time of enrollment

Where it's running

  • Select: Al-Azhar University Hospital, Assiut•
    Asyut, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.